Celecoxib/tramadol
Appearance
Combination of | |
---|---|
Celecoxib | Nonsteroidal anti-inflammatory drug (NSAID) |
Tramadol hydrochloride | Opioid agonist |
Clinical data | |
Trade names | Seglentis |
Other names | E-58425 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]
Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]
References
[edit]- ^ a b c "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
- ^ "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 18 October 2021.
- ^ "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.
External links
[edit]- "Celecoxib". Drug Information Portal. U.S. National Library of Medicine.
- "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov